What is the 13F Pro Quality Score for TXMD?

13F Pro ranks TherapeuticsMD, Inc. (TXMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TXMD's current score at https://13fpro.ai/research/TXMD (free sign-up required for the full ranking).

Where does 13F Pro source TXMD data?

All TherapeuticsMD, Inc. fundamentals and ownership data come directly from SEC EDGAR. TherapeuticsMD, Inc. files with the SEC under CIK 25743. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TXMD in?

TherapeuticsMD, Inc. (TXMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TXMD research updated on 13F Pro?

TXMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TherapeuticsMD, Inc.(TXMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 25743 TXMD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TXMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TherapeuticsMD, Inc. (TXMD), a Healthcare sector company. TXMD is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), TherapeuticsMD, Inc. reports quarterly revenue of $724.0K, net income of $95.0K, an operating margin of -99.9%. Top institutional holders of TXMD by reported 13-F value include Rubric Capital Management, Clearline Capital, Squadron Capital Management, based on the most recent SEC filings. TXMD trades on the Nasdaq exchange and files with the SEC under CIK 25743. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TXMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TherapeuticsMD, Inc. directly from SEC EDGAR. TherapeuticsMD, Inc.'s 13F Pro composite quality score has ranged between 3 and 40 since 2022, currently 8.1 — a declining long-term trajectory across 11 quarterly and live scoring snapshots.

Revenue

Q1 2026

$724.0K

Net Income

Q1 2026

$95.0K

Free Cash Flow

Q1 2026

$944.0K

Operating Margin

Q1 2026

-99.9%

ROIC

Q1 2026

-2.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-98.1% YoY

$1.3MFY 2023

FY20 $64.9MFY21 $2.6MFY22 $70.0MFY23 $1.3M

Net Income

-109.2% YoY

$-10.3MFY 2023

FY20 $-183.5MFY21 $-172.4MFY22 $112.0MFY23 $-10.3M

Operating Income

-815.6% YoY

$-8.5MFY 2023

FY20 $-155.5MFY21 $-79.6MFY22 $1.2MFY23 $-8.5M

EPS (Diluted)

-108.3% YoY

$-0.99FY 2023

FY20 —FY21 $-21.66FY22 $11.96FY23 $-0.99

Total Assets

-52.1% YoY

$43.3MFY 2023

FY20 $181.6MFY21 $169.5MFY22 $90.5MFY23 $43.3M

Total Debt

—FY 2023

FY20 $237.7MFY21 $376.5MFY22 —FY23 —

Op. Cash Flow

—FY 2023

FY20 $-159.5MFY21 $-142.7MFY22 —FY23 —

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$1.3M -98.1%	$70.0M +2619.1%	$2.6M -96.0%	$64.9M +30.7%	$49.6M +208.4%	$16.1M
Net Income	$-10.3M -109.2%	$112.0M +165.0%	$-172.4M +6.1%	$-183.5M -4.2%	$-176.1M -32.8%	$-132.6M
Operating Income	$-8.5M -815.6%	$1.2M +101.5%	$-79.6M +48.8%	$-155.5M -2.9%	$-151.2M -16.1%	$-130.2M
EPS (Diluted)	$-0.99 -108.3%	$11.96 +155.2%	$-21.66	—	—	—
Total Assets	$43.3M -52.1%	$90.5M -46.6%	$169.5M -6.7%	$181.6M -31.7%	$266.0M +25.5%	$212.0M
Total Debt	—	—	$376.5M +58.4%	$237.7M +22.1%	$194.6M +165.2%	$73.4M
Operating Cash Flow	—	—	$-142.7M +10.5%	$-159.5M +3.8%	$-165.7M -55.1%	$-106.8M

AI Insight: TXMD Financial Trends

TherapeuticsMD remains unprofitable with negligible revenue; equity stable at $27M but operational losses persist.

• Revenue consistently near $1M across Q2 2025–Q1 2026; no growth trajectory evident.

• Net income oscillated between $-1M and $+1M; Q1 2026 returned to breakeven ($0M) after Q4 2025 loss.

• Operating income negative in all recent quarters (Q1 2025–Q1 2026), ranging $-2M to $-1M.

• Shareholder equity held steady at $27M since Q4 2024; no deterioration but no growth.

⚠ Sustained operating losses and minimal revenue suggest company is not yet commercially viable.

⚠ Operating cash flow data absent; inability to assess cash burn rate and runway.

Get alerted when TXMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TherapeuticsMD, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TXMD

Rubric Capital Management LP
$2.4M1,192,191 sh
Clearline Capital LP
$1.3M635,222 sh
Squadron Capital Management LLC
$849.3K420,421 sh
VANGUARD CAPITAL MANAGEMENT LLC
$714.5K353,697 sh
Tejara Capital Ltd
$698.6K345,852 sh
ADAR1 Capital Management, LLC
$422.6K209,210 sh
RENAISSANCE TECHNOLOGIES LLC
$295.3K146,200 sh
MORGAN STANLEY
$261.0K129,217 sh
BlackRock, Inc.
$232.6K115,145 sh
GEODE CAPITAL MANAGEMENT, LLC
$221.9K109,817 sh

Fund	Value	Shares
Rubric Capital Management LP	$2.4M	1,192,191
Clearline Capital LP	$1.3M	635,222
Squadron Capital Management LLC	$849.3K	420,421
VANGUARD CAPITAL MANAGEMENT LLC	$714.5K	353,697
Tejara Capital Ltd	$698.6K	345,852
ADAR1 Capital Management, LLC	$422.6K	209,210
RENAISSANCE TECHNOLOGIES LLC	$295.3K	146,200
MORGAN STANLEY	$261.0K	129,217
BlackRock, Inc.	$232.6K	115,145
GEODE CAPITAL MANAGEMENT, LLC	$221.9K	109,817

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TXMD on your watchlist

Track score changes the day TherapeuticsMD, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TXMD a good stock to buy?

13F Pro's AI-powered analysis of TherapeuticsMD, Inc. (TXMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TXMD are available on the TXMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TXMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TXMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TherapeuticsMD, Inc.'s investment landscape.